To Assess the Effects of Valsartan on Albuminuria/Proteinuria in Hypertensive Patients With Type 2 Diabetes Mellitus
Status:
Completed
Trial end date:
2009-11-01
Target enrollment:
Participant gender:
Summary
This study is designed to assess the efficacy of the different dosage forms of Valsartan[80,
160, and 320 mg] in reducing microalbuminuria/proteinuria in hypertensive patients with type
2 diabetes.